NorthEdge Capital has invested in RoukenBio, a Scottish CRO specializing in immunology research, to support its expansion and innovation in the life sciences sector.

Information on the Target

RoukenBio, formerly known as Antibody Analytics, is a prominent contract research organization (CRO) based in Scotland, specializing in high-quality immunology research services for a global clientele. The company focuses on assisting biopharmaceutical organizations in overcoming significant scientific hurdles encountered during the pre-clinical drug discovery process. By delivering exceptional data quality, RoukenBio aims to accelerate the development of new healthcare solutions, thereby enhancing health outcomes worldwide.

RoukenBio is particularly dedicated to supporting the advancement of antibody-targeted therapeutics, complex biologics, and immunotherapies. This focus enables their clients to successfully transition the most promising drug candidates into clinical trials. Under the leadership of CEO Andy Upsall, RoukenBio is poised for significant growth, reflecting a commitment to innovation and excellence in service delivery.

Industry Overview in Scotland

The life sciences sector in Scotland is a vibrant and rapidly growing industry, recognized for its collaboration between research institutions and commercial enterprises. Scotland boasts a robust framework for life sciences, supported